Boehringer Ingelheim, Eli Lilly Collaborate in Clinical Trial for Metastatic Breast Cancer Combo Therapy

Boehringer Ingelheim, Eli Lilly Collaborate in Clinical Trial for Metastatic Breast Cancer Combo Therapy
Boehringer Ingelheim and Eli Lilly will collaborate on a Phase 1b clinical trial to assess the safety and tolerability of Boehringer Ingelheim’s BI 836845 in combination with Lilly’s abemaciclib (LY2835219) to treat patients with HR+/HER2- metastatic breast cancer (mBC). The companies believe these two agents used in combination could offer more complete pathway interference and potentially extend cell cycle arrest. For patients with HR+/HER2- mBC, this could reverse resistance to hormone therapy. The new collaboration, which is based on Phase 1b data, has the potential to expand to Phase 2 clinical trials in patients with HR+/HER2- mBC as well as other solid tumors. Patient enrollment is planned to commence later this year. Boehringer Ingelheim will act as sponsor of the trial program. Richard Gaynor, MD, senior vice president of product development and medical affairs for Lilly Oncology, said in a press release the company was pleased to partner with Boehringer Ingelheim for the combination project, and that Lilly has an active Phase 3 trial underway for abemaciclib. “For patients living with metastatic breast cancer, the limited treatment options available make this an important area of fo
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.